Advanced Skin Cancers Coverage from Every Angle
Editor:
Soo Park, MD
Advertisement
Advertisement

News

AACR 2025: Socioeconomic Status Linked to Disparities in Merkel Cell Carcinoma Outcomes
AACR 2025: AI Models May Help Diagnose Nonmelanoma Skin Cancers in Resource-Limited Regions
Mohs Surgery vs Wide Local Excision in cSCC
Prognostic Factors Seem to Favor Women in Global Study of Patients With Cutaneous Melanoma
Survivn Overexpression Tied to BCC Clone Size
Efficacy of Antibody Clones in Diagnosing Merkel Cell Carcinoma
Molecular Profile of Japanese Patients With Advanced Melanoma
Can Macrophage Activity Predict Immunotherapy Response in Patients With Melanoma?
Can Response to PD-L1 Inhibitors Influence Treatment Choices in Merkel Cell Carcinoma?
Antithrombotic Therapy Concomitant With Immunotherapy in Advanced Melanoma
Neoadjuvant T-VEC: An Option for Cutaneous Basal Cell Carcinoma?
Subcutaneous Injection of Nivolumab and Hyaluronidase-nvhy Approved by the FDA
Evaluating Mortality Risk Based on Breslow Thickness in Patients With Melanoma
Merkel Cell Carcinoma and Melanoma: Trends and Survival in the United States
Priority Review Granted by FDA for RP1 Plus Nivolumab in Advanced Melanoma
C-POST Trial: Cemiplimab-rwlc After Surgery for High-Risk Squamous Cell Skin Cancer
ATLAS: A New Mnemonic for Symptoms Linked to Melanoma Recurrence
Can Focused Ultrasound Improve Immunotherapy Response in Melanoma? Pilot Study Intends to Find Out
Intradermal Injection of Axitinib Being Tested in Nonmelanoma Skin Cancers
For Advanced Squamous Cell Skin Cancer: FDA Approves PD-L1–Blocking Antibody
Epigenetic Work Reveals Potential Biomarker in Cutaneous Melanoma
Under Study in Squamous Cell Skin Cancer: Neoantigen Therapy Plus Pembrolizumab
Investigating Immunotherapy Resistance in Merkel Cell Carcinoma
Immune Biomarkers as Predictors of Survival and Risk in Patients With Melanoma
Immunotherapy Combination Under Study in High-Risk Resectable Melanoma
Advanced Merkel Cell Carcinoma: How Effective Is Immunotherapy Rechallenge?
SITC 2024: Predicting Recurrence With ctDNA Biomarker in High-Risk Melanoma
Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.